

Docket No. 203510US77

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William M. CANFIELD

SERIAL NO: 10/023,890

GAU: 1652

FILED: December 21, 2001

EXAMINER:

FOR: METHOD OF PRODUCING GLYCOPROTEINS HAVING REDUCED COMPLEX CARBOHYDRATES IN MAMMALIAN CELLS

RECEIVED

JUL 24 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Richard L. Chinn, Ph.D.

Registration No. 34,305




22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Daniel J. Pereira, Ph.D.

Registration No. 45,518

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

203510US77

SERIAL NO.

10/023,890

RECEIVED

JUL 24 2003

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

William M. CANFIELD

FILING DATE

December 21, 2001

GROUP

1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	99/31117	06/24/99	WIPO		
	AP					
	AQ					
	AR					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AS	Ke-Wei ZHAO, et al., "Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphotransferase", Glycobiology, Vol. 2, no. 2, pp. 119-125, 1992
AT	Takahiro NAGASE, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New(cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", DNA Research, Vol. 6, pp. 337-345, 1999
AU	XP-002226188, "KIAA1208 protein (Fragment)", From Takahiro NAGASE, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New(cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", DNA Research, Vol. 6, pp. 337-345, 1999
AV	XP-002226187, "Basic domain/leucine zipper transcription factor (Fragment), From CORDES, et al., "The mouse segmentation gene <i>kr</i> encodes a novel basic domain-leucine zipper transcription factor" (1994), Cell, Vol. 7, No. 9, pp.1025-1034

☐ Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

203510US77

SERIAL NO.

10/023,890

RECEIVED

JUL 24 2003

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

William M. CANFIELD

FILING DATE

December 21, 2001

GROUP

1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						
	CL						
	CM						
	CN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CO					
	CP					
	CQ					
	CR					
	CS					
	CT					
	CU					
	CV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	CW	Ritva TIKKANEN, et al., "Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase", The EMBO Journal, vol. 16, No. 22, pp. 6684-6693, 1997		
	CX	Fumito MATSUURA, et al., "Human alpha-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells", Glycobiology, vol. 8, no. 4, pp. 329-339, 1998		
	CY	Shiroh MAGUCHI, et al., "Elevated Activity and Increased Mannose-6-phosphate in the Carbohydrate Moiety of Cathepsin D from Human Hepatoma", Cancer Research, Vol. 48, pp. 362-367, January 15, 1988		
	CZ	Norman W. Barton, et al., "Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 1913-1916, March 1990		<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.